Wall Street is often blamed for reducing corporate managers’ understanding of business to a single, gameable measure of ...
That “waste-to-value” is increasingly getting quiet attention from private equity and infrastructure investors.
Private-equity executives entered 2025 with high hopes for a dealmaking recovery that is lifting payouts to fund investors ...
Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...
In 2025’s go-go leveraged debt markets, everything is up for negotiation, but a trio of investor protections are proving to ...
A shakeout in the private-equity industry is forcing firms to adapt or get left behind.
As stakeholders recalibrate their approaches, secondaries offer a proving ground for innovative capital strategies that could influence private equity far into the future.
In 2024, global private equity and venture capital transaction value and volume in biotechnology declined to their lowest ...
The era of ultralow interest rates fostered a leveraged buyout boom and a desperate hunger for yield among investors. The ...
Learn from Dr. Roy Smythe about the promises and pitfalls of private equity and venture capital in the evolving healthcare ...
Health Affairs' Jeff Byers welcomes Senior Editor Kathleen Haddad back to the program to discuss two recent reports exploring the impacts of private equity on the US health care system.
In the past decade, private equity investors have spent over $1 trillion in acquiring health care entities — ranging from hospitals and nursing homes to private physician practices. While it may be ...